Middle East and Africa Persistent Corneal Epithelial Defects Treatment Market - Industry Trends and Forecast to 2027
Short Description
Middle East and Africa persistent corneal epithelial defects treatment market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others), Type (Devices, Medication), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Saudi Arabia, South Africa, Egypt, U.A.E., Israel and rest of Middle East & Africa)
Market Definition:
A persistent corneal epithelial defect is a multifactorial condition of the cornea that results from the failure of mechanism of the corneal epithelialization which leads to the disruption in the corneal surface and exposed the eyes vulnerable to the herpetic infections, stromal ulceration and scarring. These defects may persist for several days or even months and it is generally characterized by decreased corneal sensitivity and poor corneal healing. It is manifested by many chronic conditions of the eyes such as limbal cell deficiency, ocular inflammatory disorders, neurotrophic keratitis, herpes simplex and many others.
In healthy eyes, corneal epithelialization plays a crucial role in wound healing and corneal metabolism and thus maintains the cornea’s functionality and integrity. Injury to the corneal surface requires complex corneal epithelialization procedure which involves limbal stem cells acting as, proliferation, cell differentiation and regenerating of the extracellular matrix.
Market Segmentation:
Middle East and Africa persistent corneal epithelial defects treatment market is categorized into five notable segments which are based on the basis of clinical causes, type, end user and distribution channel.
• On the basis of clinical causes, the market is segmented into epithelial/limbal stem cell deficiency, inflammatory disease, neurotrophic keratitis (NK) and others
• On the basis of type, the market is segmented into devices and medication.
• On the basis of end user, the market is segmented into hospitals, homecare, specialty clinics and others.
• On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Market Players
The key market players for Middle East and Africa persistent corneal epithelial defects treatment market are listed below:
• Dompé Farmaceutici S.p.A
• Novartis AG
• Allergan
• Next Biosciences
• Katena Products. Inc.
• Johnson & Johnson Services, Inc.
• Hunt Valley PharmaLAB
• Laboratoires THEA S.A.S
• Skye Biologics Inc.
• I-MED Pharma inc.
• Almirall, S.A
• Ocular Science, Inc.
• Kala Pharmaceuticals
• Bausch Health
• Integra LifeSciences Corporation
• BioTissue (A Subsidiary of TissueTech, Inc.)
The single user license is non-downloadable and non-printable. Global Site license allows these actions.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Products Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Market Overview
- 4.1 Drivers
- 4.1.1 Increasing Prevalence Of Persistent Corneal Epithelial Defects And Other Related Complications
- 4.1.2 Rising Cases Of Eye Surgeries And Usage Of Contact Lenses
- 4.1.3 Growing Ageing Population Augmenting Towards The Pced Condition
- 4.1.4 Increase In Mechanical Traumas Cases
- 4.2 Restraint
- 4.2.1 Stringent Regulatory Procedures
- 4.2.2 Unmet Medical Needs For The Treatment Of Pced
- 4.2.3 High Cost Of Persistent Corneal Epithelial Defects Treatments
- 4.3 Opportunities
- 4.3.1 Development Of Novel Therapeutics
- 4.3.2 Increasing Awareness About Diagnosis And Treatment Of The Disease
- 4.3.3 Strategic Initiatives By Market Players
- 4.3.4 Emerging Market Economy Creates Significant Opportunities
- 4.4 Challenges
- 4.4.1 Dependency On Third Party Suppliers
- 5 Premium Insights
- 6 Epidemiology
- 7 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, By Clinical Causes
- 7.1 Overview
- 7.2 Inflammatory Disease
- 7.3 Neurotrophic Keratitis (Nk)
- 7.4 Epithelial/Limbal Stem Cell Deficiency
- 7.5 Others
- 8 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, By Type
- 8.1 Overview
- 8.2 Devices
- 8.2.1 Bandage Contact Lens
- 8.2.2 Amniotic Membrane Grafts
- 8.2.3 Punctal Plugs
- 8.2.3.1 Silicone Plug
- 8.2.3.2 Collagen Plugs
- 8.2.4 Corneal Transplants
- 8.2.4.1 Keratoplasty
- 8.2.4.2 Keratoprosthesis
- 8.3 Medication
- 8.3.1 Drug Type
- 8.3.1.1 Lubricants
- 8.3.1.2 Prophylactic Topical Antibiotics
- 8.3.1.2.1 Polymixin B–trimethoprim + Fluoroquinolone
- 8.3.1.2.2 Fluoroquinolone
- 8.3.1.3 Topical Ophthalmic Steroids
- 8.3.1.4 Autologous Serum Tears/Autologous Serum Eye Drops
- 8.3.1.5 Tetracyclines
- 8.3.1.6 Human Nerve Growth Factor (Oxervate)
- 8.3.1.7 Wound Healing Agents
- 8.3.1.8 Others
- 8.3.2 Route Of Administration
- 8.3.2.1 Topical
- 8.3.2.2 Oral
- 9 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, By End User
- 9.1 Overview
- 9.2 Hospitals
- 9.3 Homecare
- 9.4 Specialty Clinics
- 9.5 Others
- 10 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, By Distribution Channel
- 10.1 Overview
- 10.2 Hospital Pharmacies
- 10.3 Retail Pharmacies
- 10.4 Online Pharmacies
- 11 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, By Geography
- 11.1 Middle East And Africa
- 11.1.1 Uae
- 11.1.2 Saudi Arabia
- 11.1.3 South Africa
- 11.1.4 Israel
- 11.1.5 Kuwait
- 11.1.6 Egypt
- 11.1.7 Rest Of Middle East And Africa
- 12 Middle East And Africa Persistent Corneal Epithelial Defects Treatment Market, Company Landscape
- 12.1 Company Share Analysis: Middle East And Africa
- 13 Company Profile
- 13.1 Johnson & Johnson Services, Inc.
- 13.1.1 Company Snapshot
- 13.1.2 Revenue Analysis
- 13.1.3 Company Share Analysis
- 13.1.4 Product Portfolio
- 13.1.5 Recent Developments
- 13.2 Allergan
- 13.2.1 Company Snapshot
- 13.2.2 Revenue Analysis
- 13.2.3 Company Share Analysis
- 13.2.4 Product Portfolio
- 13.2.5 Recent Development
- 13.3 Bio-tissue (A Subsidiary Of Tissuetech, Inc.)
- 13.3.1 Company Snapshot
- 13.3.2 Company Share Analysis
- 13.3.3 Product Portfolio
- 13.3.4 Recent Developments
- 13.4 Laboratoires Théa S.A.S
- 13.4.1 Company Snapshot
- 13.4.2 Company Share Analysis
- 13.4.3 Product Portfolio
- 13.4.4 Recent Development
- 13.5 Novartis Ag
- 13.5.1 Company Snapshot
- 13.5.2 Revenue Analysis
- 13.5.3 Product Portfolio
- 13.5.4 Recent Development
- 13.6 Bausch Health
- 13.6.1 Company Snapshot
- 13.6.2 Revenue Analysis
- 13.6.3 Product Portfolio
- 13.6.4 Recent Development
- 13.7 Integra Lifesciences Corporation
- 13.7.1 Company Snapshot
- 13.7.2 Revenue Analysis
- 13.7.3 Product Portfolio
- 13.7.4 Recent Development
- 13.8 Almirall, S.A
- 13.8.1 Company Snapshot
- 13.8.2 Revenue Analysis
- 13.8.3 Product Portfolio
- 13.8.4 Recent Development
- 13.9 Dompé Farmaceutici S.P.A.
- 13.9.1 Company Snapshot
- 13.9.2 Product Portfolio
- 13.9.3 Recent Developments
- 13.10 Hunt Valley Pharmalab
- 13.10.1 Company Snapshot
- 13.10.2 Product Portfolio
- 13.10.3 Recent Development
- 13.11 I-med Pharma Inc.
- 13.11.1 Company Snapshot
- 13.11.2 Product Portfolio
- 13.11.3 Recent Development
- 13.12 Kala Pharmaceuticals
- 13.12.1 Company Snapshot
- 13.12.2 Product Portfolio
- 13.12.3 Recent Developments
- 13.13 Katena Products. Inc.
- 13.13.1 Company Snapshot
- 13.13.2 Product Portfolio
- 13.13.3 Recent Developments
- 13.14 Next Biosciences
- 13.14.1 Company Snapshot
- 13.14.2 Product Portfolio
- 13.14.3 Recent Development
- 13.15 Ocular Science, Inc.
- 13.15.1 Company Snapshot
- 13.15.2 Product Portfolio
- 13.15.3 Recent Development
- 13.16 Skye Biologics Inc.
- 13.16.1 Company Snapshot
- 13.16.2 Product Portfolio
- 13.16.3 Recent Development
- 14 Questionnaire
- 15 Related Reports
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook